January 28, 2015 11:56 AM ET

Pharmaceuticals

Company Overview of Relypsa, Inc.

Company Overview

Relypsa, Inc., a pharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. The company’s principal product candidate includes Patiromer, a non-absorbed potassium binder that completed Phase 3 clinical trial for the treatment of hyperkalemia. It also offers RLY6002, a pre-clinical product candidate that evaluates as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. The company was founded in 2007 and is headquartered in Redwood City, California.

700 Saginaw Drive

Redwood City, CA 94063

United States

Founded in 2007

99 Employees

Phone:

650-421-9500

Key Executives for Relypsa, Inc.

Chief Executive Officer
Age: 49
Total Annual Compensation: $287.3K
Founder
Total Annual Compensation: $172.5K
Chief Medical Officer and Senior Vice President
Age: 43
Total Annual Compensation: $321.9K
Senior Vice President of Pharmaceutical Development & Regulatory Affairs
Age: 61
Total Annual Compensation: $304.0K
Compensation as of Fiscal Year 2013.

Relypsa, Inc. Key Developments

Relypsa, Inc. Appoints Helen Torley as Director

Relypsa, Inc. announced that Helen Torley, M.B. Ch.B., M.R.C.P., has been appointed to the company's board of directors, bringing the number of directors to nine. Dr. Torley, current president and chief executive officer of Halozyme Therapeutics, brings to the board significant industry experience and deep knowledge and expertise in development and commercialization of biopharmaceutical products, including several recent successful product launches. Prior to joining Halozyme in January 2014, Dr. Torley served as executive vice president and chief commercial officer for Onyx harmaceuticals, where she oversaw the collaboration with Bayer on Nexavar and Stivarga and the U.S. launch of Kyprolis. From 2003 to 2011, she held management positions at Amgen, most recently as vice president and general manager of the U.S. Nephrology Business Unit and the U.S. Bone Health Business Unit. Previously, she held various senior management positions at Bristol-Myers Squibb, including regional vice president of Cardiovascular and Metabolic Sales and head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as vice president of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas.

Relypsa, Inc. - Analyst/Investor Day

Relypsa, Inc. - Analyst/Investor Day

Relypsa, Inc.(NasdaqGS:RLYP) added to NASDAQ Biotechnology Index

Relypsa, Inc. will be added to the NASDAQ Biotechnology Index.

Similar Private Companies By Industry

Company Name Region
Intellikine, Inc. United States
SinoFresh Healthcare Inc. United States
Capricorn Pharma, Inc. United States
Vemas Herb & Health United States
Knoll Pharmaceutical Company United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 30, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Relypsa, Inc., please visit www.relypsa.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.